SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : YEEHAW CANDIDATES
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: D. K. G. who wrote (7129)6/23/2005 10:21:07 PM
From: D. K. G.  Read Replies (1) of 23958
 
4:11PM Inkine Pharm to be acquired by Salix Pharma for $3.55/share (INKP) 2.17 +0.07:Salix Pharma (SLXP) and InKine Pharma (INKP) announce that the two companies have entered into a definitive merger agreement under which InKine stockholders will receive Salix common stock valued at $3.55 per share of InKine common stock, or approx $190 mln in equity value. On a GAAP basis, the transaction is expected to be EPS neutral to Salix in 2006 and significantly accretive thereafter.

==============================================

I made some $$$ but seems too cheap.
Shareholders are getting ripped off!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News